Z-VAD-FMK

Catalog No.S7023

Z-VAD-FMK is a cell-permeable, irreversible pan-caspase inhibitor, blocks all features of apoptosis in THP.1 and Jurkat T-cells.

Price Stock Quantity  
USD 117 In stock
USD 470 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Z-VAD-FMK Chemical Structure

Z-VAD-FMK Chemical Structure
Molecular Weight: 467.49

Validation & Quality Control

Customer Product Validation(2)

Quality Control & MSDS

Product Information

  • Compare Caspase Inhibitors & Activators
    Compare Caspase Products
  • Research Area

Product Description

Biological Activity

Description Z-VAD-FMK is a cell-permeable, irreversible pan-caspase inhibitor, blocks all features of apoptosis in THP.1 and Jurkat T-cells.
Targets Pan-caspase [1]
(THP.1, Jurkat T-cells)
In vitro Z-VAD-FMK (10 mM) inhibits apoptosis in THP.1 cells. Z-VAD-FMK (10 μM) inhibits activation of PARP protease activity in control THP.1 cell lysates. Z-VAD-FMK (10 mM) inhibits the processing of CPP32 in intact THP.1 and Jurkat cells. [1] Z-VAD-FMK (50 μM) cotreatment abolishes the apoptotic morphology of camptothecin-treated HL60 cells. Z-VAD-FMK (50 μM) blocks camptothecin-induced DNA fragmentation in HL60 cells. [2] Z-VAD-FMK (50 μM) inhibits cell death following dSMN dsRNA-induced apoptosis in S2 cells. Z-VAD-FMK (50 μM) increases the percentage of transfected cells surviving from 26% to 63% in S2 cells. [3] Z-VAD-FMK (> 100 μM) enhances TNFα-induced neutrophil apoptosis, lower concentrations (1-30 μM) completely blocks TNFα-stimulated apoptosis in human neutrophils. [4] Z-VAD-FMK (10 mM) inhibits apoptosis in anterior stromal keratocytes. Z-VAD-FMK (10 mM) inhibits apoptosis in anterior stromal keratocytes detected with the TUNEL assay. [5]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
GC1aNGmzZYtCeG:ydH;zbZMhSXO|YYm=NHXMS442OM7:TR?=NVzkV5E4OjSqM33O[olv\GmlYYTld{BiKHC{b4TlZ5RqfmViZX\m[YN1KGGpYXnud5Qh\XSxcH;zbYRmMnjjNlYyPjlyN{W=
HGL5M3PhV2Fxd3C2b4Ppd{BCe3OjeR?=MXy1NO69VQ>?MX[yOIg>M3;tSolv\GmlYYTld{BiKHC{b4TlZ5RqfmViZX\m[YN1KGGpYXnud5Qh\XSxcH;zbYRmM4jtSVI3OTZ7MEe1
HepG2NY\Ub2doSXCxcITvd4l{KEG|c3H5NYPJTlFkOjEQvF2=MU[xbC=>MVHheJRmdnWjdHXkJJRp\SCjcH;weI91cWNiaX7keYN1cW:wIH;mJGlKUS1zMNMgM1\3cFI3OTZ2N{m1
BEL-7402NF7LN5pCeG:ydH;zbZMhSXO|YYm=MmrTNlDPxE1?NXfXVHVrOWh?MlPjZZR1\W63YYTl[EB1cGViYYDvdJRwfGmlIHnu[JVkfGmxbjDv[kBKUUlvMUFCpC=>NYX4XXJqOjZzNkS3PVU>
CEFMY\LbY5ie2ViQYPzZZk>M17mOVAtOzNuNkesNVAx|ryPNUO4VVNyOTWvaX6=NHfUeJJld3ewLYLl[5Vt[XSnczDQVkBmdnq7bXWgZYN1cX[rdImgeI8hPDExvJWgZZQhOTByzszNNEX4fYszPjFyMkOzPS=>
SP2/0M2\lOGFxd3C2b4Ppd{BCe3OjeR?=NXG4foE1OTByzszNNFvTSVQycA>?NIq4U2ZFVVORNIqzVXRjdG:la4OgeIhmKGGyb4D0c5NqeyCxZjDTVFIwOCClZXzsdy=>MUeyOlA4PDd|Mh?=
HUVEC-2cMVTBdI9xfG:|aYOgRZN{[Xl?M13Gd|Ux|ryPMUO2bC=>M3jvXYRm[3KnYYPl[EB1cGVib4itUGRNNWmwZIXj[YQh[XW2b4DoZYd6M1jsclI3ODJzN{K5
U1MoLqRZBweHSxc3nzJGF{e2G7NIXuN|UxNTFyMN88US=>NV24VXdtOmh?NFPMeWNz\WS3Y3XzJIRzfWdvaX7keYNm\CCjcH;weI9{cXNiYX7kJJN2[nOncYXlcpQhUEmYLUGgdoVxdGmlYYTpc44hcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>NFTqWXEzPTl6MEm0Ni=>
ACH-2MXPBdI9xfG:|aYOgRZN{[Xl?MUmwMVIxOM7:TR?=M33SRlJpNXmyWJRHemWmdXPld{BlenWpLXnu[JVk\WRiYYDvdJRwe2m|IHHu[EB{fWK|ZYH1[Y51KEiLVj2xJJJmeGyrY3H0bY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVzMX6yOVk5ODl2Mh?=
U1NIDmTXVMcW6jc3WgRZN{[Xl?M{HtV|ExOM7:TR?=MWWybC=>M{DHb4lvcGmkaYTzJINie3Cjc3WtNy=>NIe1WI0zPTl6MEm0Ni=>
A549/V16NVv2W4hUSXCxcITvd4l{KEG|c3H5MX[1NO69VQ>?MmXGNYg>M4j6NZJmeHKnc4Pld{BVTy:WTT3pcoR2[2WmIHHwc5B1d3Orcx?=Mm\YNlU6PDZyM{O=
SGNMYHBdI9xfG:|aYOgRZN{[Xl?NHXacJgzOG2PNGLLNnQ1QGh?NYf6UWk{cGG|IH7vJIlv\my3ZX7j[UBwdiCDSV[sJINidHCjaX6g[ZhxemW|c3nvckBweiClZXzsJIFxd3C2b4Ppdy=>NF;rSpczPTh5NE[zNy=>
HCT116 MkH2RZBweHSxc3nzJGF{e2G7NYnG[lA2PTEQvF2=MUSybC=>MlXkbY5pcWKrdIOgeIhmKGOnbHyg[IVifGhiaX7keYNm\CCkeTDESHZRM{mwSFI2QDZ6OEG4
DTK-SMEM2Wye2Fxd3C2b4Ppd{BCe3OjeR?=NXPI[4d3PTEQvF2=NWDxWWRIOmh?NHHvUG5FVVORMV\wZZJ1cWGubImgbY5pcWKrdIOgeIhmKGGyb4D0c5NqeyCrbnT1Z4VlKGK7IHL1dIl3[WOjaX7lNUnHeWRqOjV6NEO4PVc>
HL-60M{LIO2Fxd3C2b4Ppd{BCe3OjeR?=MVO1NO69VQ>?NETBdVE1QGh?NYrjXFg3emWmdXPld{Bk\WyuIHTlZZRpKGOjdYPl[EBjgSCVS1mtTWkhfHKnYYTt[Y51yqB?NFPBT3ozPTh{NEC0Ny=>
U937MYjBdI9xfG:|aYOgRZN{[Xl?MnPaOVDPxE1?NIHmco01QGh?MlW0doVlfWOnczDj[YxtKGSnYYToJINifXOnZDDifUBUU0lvSVmgeJJm[XSvZX70xsA>NY\6T4pFOjV6MkSwOFM>
A549MVrBdI9xfG:|aYOgRZN{[Xl?M{i1SlIxKM7:TR?=NWLmboZIOjSqNVnPdnZUemWmdXPld{Bk\WyuIHTlZZRpKGOjdYPl[EBjgSCKRlPQJJRz\WG2bXXueC=>M4npSFI2Pzl2MUS5
HeLaMWjBdI9xfG:|aYOgRZN{[Xl?M1zJV|Ex|ryPNGDhbJM1QGh?MYnk[YNtcW6nczD0bIUhemG2ZTDv[kBieG:ydH;zbZMh\HKjbXH0bYNidGy7MWiyOVc4OjV2NR?=
SGC-7901NW\CPWlTSXCxcITvd4l{KEG|c3H5NFzBO5MzOMLizszNMUmxbC=>MkXMbY5pcWKrdIOgeIhmKGOnbHyg[IVifGhiaX7keYNm\CCkeTDvfIFtcXCuYYTpci=>NIm4WWgzPTd4N{C3Oi=>
MCF-7NEPzV2VCeG:ydH;zbZMhSXO|YYm=NHfTfYIyOM7:TR?=MUGybC=>M3rqUolvcGmkaYTzJJRp\SClZXzsJIRm[XSqIHnu[JVk\WRiYomgN2I>MoHwNlU4OjJzMUS=
A549M3r6R2Fxd3C2b4Ppd{BCe3OjeR?=NIfDN5YyOCEQvF2=NWfISmV3OjSqNFrZO4pFVVORMWPwdo9ud3SnczDIRmMufHKnYYTl[EBCPTR7IHPlcIwhe3W{dnn2ZYwhLiCjdITlcpVifGW|IITo[UBkdGWjdnXkJHBCWlBiZYjwdoV{e2mxbh?=M2XWTFI2Pjh|NU[4
U87Mli3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHLZenc2OM7:TR?=MomzNYg>NHjZT5Bz\WOxdnXyd{Bk\WyuIHfyc5d1cCCocn;tJHROYiC2cnXheI1mdnR?NVSwVpBCOjV4OEG2Olg>
Neocortical NeuronM1TaS25mfXKxdH;4bYNqfHliQYPzZZk>M4fGe|ExOM7:TR?=NWLLNWF6OWh?MW\hcpRi\2:waYrld{BJd2mjbXnk[UBCNUmwZIXj[YQhVmW3cn;0c5hq[2m2eR?=MYGyOVY4PTByMR?=
Primary human placental cytotrophoblastsNGXoS4NCeG:ydH;zbZMhSXO|YYm=NX3KSYc3OzEQvF2=MYGyOIg>MmjWSG1UVw>?MXXy[ZZmenOnczD0bIUhcW6qaXLpeIlwdiCxZjCxNe6zNUiVREKgZpkhfHKrY3zvd4FvyqB?M3rDUlI2PjR{NUmy
MMM1;m[WFxd3C2b4Ppd{BCe3OjeR?=NV\2dVJNPTEQvF2=NUTmdmlXOjCvaX6=Mmq4dIFzfGy7IHnubIljcXS|IGPIT{1qdmS3Y3XkJEBk\WyuIHTlZZRpMWOyOVU{ODB7OB?=
DLD1NV60fIlwSXCxcITvd4l{KEG|c3H5NG\UNW8zOMLizszNNYL3bYxiOWh?NXrSTplteGG{dHz5JJJmfmW{c3XzJINmdGxiYYDvdJRwe2m|IHPheZNm\CCkeTDXV3AyMnzuNlU2OjR{NE[=
MDA-MB-231MVfDfZRwfG:6aXPpeJkhSXO|YYm=MXSxNO69VQ>?M1LoeFFpNEDY[mZifWevZX70d{Bk\WyuIHTlZZRpKGGodHXyJGNJXUFidILlZZRu\W62NInkXGEzPTV{MUWwNS=>
MKN28NVjrOFdwSXCxcITvd4l{KEG|c3H5NH7qSpYyOM7:TR?=MmnsN|BucW5?NHj4eWxFVVORMXHpcohq[mm2czDUUmYu|rFicHz1d{BEUFhvaX7keYNm\CCjcH;weI9{cXN?MkDLNlU2OTN7NkC=
HL-60NUDmfpE5S3m2b4TvfIlkcXS7IFHzd4F6Mnv0NVAx|ryPNGnRNYkycA>?M1L3[WROW09?MX5CpIlueHKxdnXzJJZq[WKrbHn0fUBw\iCWQ17Bd{11emWjdHXkJINmdGy|NWPrSGJ7OjV3MEK5N|I>
AGSNY\O[JRRSXCxcITvd4l{KEG|c3H5MXKxNO69VQ>?NH;WcXYycA>?NELGOIJxemW4ZX70d{BkfXKldX3pck1qdmS3Y3XkJINt\WG4YXflJI9nKGOjc4Dhd4UuOyxiLUisJIFv\CBvOTDwdo91\Wmwcx?=NX;CS4ZuOjV2OUKyNVQ>
A549 MnHuRZBweHSxc3nzJGF{e2G7NVW2ZWx7OTEQvF2=NYrYOm9EOjSqM3[0[4Jtd2OtczDEUWFUNWmwZIXj[YQh[2ynYY\h[4Uhd2ZiY3HzdIF{\S1|IHHu[EBRSVKSIHHu[EBieG:ydH;0bYMh[2WubDDk[YF1cA>?M4XnW|I2PDN2OUi5
INS-1M1PhTmFxd3C2b4Ppd{BCe3OjeR?=MUW1NO69VQ>?MV22bC=>MonySG1UVw>?Mkix[IVkemWjc3XzJJRp\SCycn;wc5J1cW:wIH;mJIViemy7IHHwc5B1d3SrYzDj[Yxte8LiMlrmNlU1OzB6OUe=
Primary hepatocytes M1u5[mFxd3C2b4Ppd{BCe3OjeR?=NXHsfWJSPTEQvF2=NHTQfHgyQGh?M3ixT4lvcGmkaYTzJIFxd3C2b4Ppd{Bw\iCqZYDheI9kgXSnczDpcoR2[2WmIHL5JGFkfCCGIHHu[EBVVkZvzsG=M{TndVI2PDB5NUO4
L929-A NUDZeFRmS3m2b4TvfIlkcXS7IFHzd4F6MXOyNOKh|ryPMn\xNlRpMmfIbY5pcWKrdIOgWG5H|rFvaX7keYNm\CClZXzsJIRm[XSqNFnqUpczPTN7OEW0NC=>
L929-NNUTINmx6S3m2b4TvfIlkcXS7IFHzd4F6M1jJVVIxyqEQvF2=M3vveVI1cA>?NGDpfHBmdmijbnPld{Bl\WG2aDD2bYEh[XW2b3PybY5mKFSQRt8xJJBzd2S3Y4Tpc44>M33mb|I2Ozl6NUSw
Cytotoxicity AssayMoTzR4VtdCCYaXHibYxqfHliQYPzZZk>MWeyNO69VQ>?MXG0PIg>M4jESpBz\X[nboSgUWhOTC2rbnT1Z4VlKGOnbHyg[IVifGh?MY[yOVM6OjFzNh?=
COS7NXvOVm5NU2mwYYPlJGF{e2G7M3PkSVEx|ryPM4H5S|I1cA>?MVfpcoNz\WG|ZYOgZ4F{eGG|ZTCzM|ch[WO2aY\peIlmew>?MnPJNlU{QDRyMkW=
COS7M{nDeGFxd3C2b4Ppd{BCe3OjeR?=MYCxNO69VQ>?Mn\POFhpNHHQUIpx[XK2aXHscJkheHKndnXueIVlKE[FMUCxMYlv\HWlZXSgZ4VtdCCmZXH0bC=>NGf1SoIzPTN6NECyOS=>
A375M2DqSGFxd3C2b4Ppd{BCe3OjeR?=MYCzNO69VQ>?M4HJTVJpNWnXcI5QeHKndnXueJMhfGinIHTyeYcucW6mdXPl[EBRSVKSIHPs[YF3[WenNEjSfGwzPTN5NkGxOS=>
A549MWHBdI9xfG:|aYOgRZN{[Xl?NGiwbXA2OM7:TR?=NXmweoxUOjSqNFLQd3Rz\X[ncoPld{BzcWKxc3;t[UBjcW:pZX7ld4l{KGGwZDDhdI9xfG:|aYOgZ4F2e2WmIHL5JEBEcGmsb37n[IFvM{\YbVI2OzR7N{ix
A549NGixUpFCeG:ydH;zbZMhSXO|YYm=MknaNk42NTJ3zszNMVuxbC=>MYfk[YNz\WG|ZYOgeIhmKHCxcIXsZZRqd25ib3[gZZBweHSxdHnjJINmdGy|IHTldIVv\CCxbjDjc45k\W62cnH0bY9vew>?MVKyOVM1OjR{Nx?=
 NBL-W-S NYDoeohySXCxcITvd4l{KEG|c3H5NFXDTGE2OM7:TR?=NX;zXoNZOWh?MXzmeYxtgSC{ZYPjeYV{KGOnbHygeoli[mmuaYT5JIFnfGW{IFfBUnQuPjFidILlZZRu\W62NVG5bXJ[OjV|MkOyNlI>
Caki-1 NVfjNYxUSXCxcITvd4l{KEG|c3H5MlvhOFDPxE1?MmDROFhpMUTy[YR2[2W|IITo[UBvfW2kZYKgc4YhSW6wZYjpckBXNXCxc3n0bZZmKGOnbHzzMlPPNlUzPzlzOUG=
769-PNIj1VmNCeG:ydH;zbZMhSXO|YYm=MXy0NO69VQ>?MV[0PIg>NECyS3hz\WS3Y3XzJJRp\SCwdX3i[ZIhd2ZiQX7u[ZhqdiCYLYDvd4l1cX[nIHPlcIx{NVjjc5N5OjV{N{mxPVE>
H9c2M1\M[GFxd3C2b4Ppd{BCe3OjeR?=M1yw[VUx|ryPNYHt[XZmOWh?MYHpcohq[mm2czDEU3gucW6mdXPl[EBk[XOyYYPlJFMh[WO2aY\heIlwdiCkdYSgco91KHSqZTDsc5N{KG:oIHPlcIx{NHPsPIEzPTJ6M{ixPS=>
K562NWPNfIxiSXCxcITvd4l{KEG|c3H5M1fSZlUx|ryPMUW0bC=>NEnMOJdqdmirYnn0d{BL[WNvQT3pcoR2[2WmIHPlcIwh[XCxcITvd4l{NFnXVHgzPTJ2MU[xPS=>
L929NEjHbIlCeG:ydH;zbZMhSXO|YYm=NGnWXIYyOM7:TR?=NVjmVowyPmh?MnjQbY5lfWOnczDu[YNzd3C2b4Ppd{B4cXSqIGTOSi=>NGf3U4czPTF7NU[2NC=>
A549NG\PN|lCeG:ydH;zbZMhSXO|YYm=MYKxNO69VQ>?MVmzbC=>MULy[YR2[2W|IHPlcIwh[XCxcITvd4l{KGOjdYPl[EBjgSCSUWG=NHnOWGQzPTF4MU[5PS=>
MCF-7M3rr[mFxd3C2b4Ppd{BCe3OjeR?=NFzMdZAzOM7:TR?=NUPVOWc3Omh?NVzsZmkz\GWlcnXhd4V{KEuGUj3zbXJPSS2rbnT1Z4VlKGGyb4D0c5Nqew>?MXOyOVE5OjJ2MB?=
OSM1LVe2Fxd3C2b4Ppd{BCe3OjeR?=MmfVNlAwPDEQvF2=NHLQV2w4Omh?NIrudoVqdmirYnn0d{BQWyClZXzsJJZq[WKrbHn0fUBz\WS3Y4Tpc44h[nliQ{[gZ4Vz[W2rZHW=NES4blgzPTF3MkO5PS=>
HUVECsMWPBdI9xfG:|aYOgRZN{[Xl?M2fPblEx|ryPMYqybC=>NYjVeodyyqCrbnjpZol1eyCjcH;weI9{cXNiYX7kJIZi[2muaYTheIV{KGG3dH;wbIFogSCrbjDESW5XOi2rbn\lZ5Rm\CCKVW\FR5M>MkTyNlUyOzh5MEO=
EA.hy926Ml\jRZBweHSxc3nzJGF{e2G7NEK2dHoyOM7:TR?=Mo\MNog>M2DxOuKhcW6qaXLpeJMh[XCxcITvd4l{KGGwZDDmZYNqdGm2YYTld{BifXSxcHjh[5khcW5iRFXOWlIucW6oZXP0[YQhTUFwaIm5NlY>NUHFVW5HOjVzM{i3NFM>
EbsM3fmZmFxd3C2b4Ppd{BCe3OjeR?=MXyxNE0yODEQvF2=NXfJbmN{OjSqNXnCcY9JyqCPTWTTJIdmdmW{YYTpc44hemG2ZTDk[YNz\WG|ZXSgZZMhfGinIHPvcoNmdnS{YYTpc44hd2Ziej3WRWQv\m2tIHnuZ5Jm[XOnZB?=NIHycHUzPTF|NEixOy=>
JurkatMnjCRZBweHSxc3nzJGF{e2G7M1\Oe|Ix|ryPMWOyOIg>MoPLSG1UVw>?NHnYOJdx[XK2aXHscJkhcW6qaXLpeEBk\WyuIHTlZZRpKG:oIFr1dotifCClZXzsd{BqdmS3Y3XkJIJ6KDFyMEW4MWY1KGOxbXLpcoVlKHerdHigWnBCyqB?NXe1RZBVOjVzMkC3NlM>
K562MUTBdI9xfG:|aYOgRZN{[Xl?MWGwMlEuOc7:TR?=NF;qUo8ycA>?NX7SSJBlcW6qaXLpeJMh[2ynYY\h[4Uhd2ZiSGPQPVAhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>NIXDfIgzPTFzOUG4PC=>
IMR-32MoLCRZBweHSxc3nzJGF{e2G7M3LOTlQxyqEQvF5CpC=>MWqybC=>MXjk[YNz\WG|ZTDpckBieG:ydH;0bYMh[2WubIOgZ49ueGG{ZXSgeI8hXC1{IITvfIlvMkjqNlUxQDR5NUW=
RPMI 8226M2W3WmFxd3C2b4Ppd{BCe3OjeR?=NYrVb241OTByzszNNWLGdHBLOWh?MVThcI1we3RiY3;tdIxmfGWueTDicI9kc3NiY3XscEBl\WG2aDDjZZV{\WRiYomgcoVkem:|dHH0bY4uOQ>?MoPENlUxOzd6NUG=
U266 NEjqUW5CeG:ydH;zbZMhSXO|YYm=M37leVExOM7:TR?=NFH4UGsycA>?NWf4VpNWeGG{dHnhcIx6KGKub3Prd{Bk\WyuIHTlZZRpKGOjdYPl[EBjgSCwZXPyc5N1[XSrbj2xMniyNlUxOzd6NUG=
H929 M{XCfmFxd3C2b4Ppd{BCe3OjeR?=M2C1UlExOM7:TR?=MnHuNYg>MYrwZZJ1cWGubImgZoxw[2u|IHPlcIwh\GWjdHigZ4F2e2WmIHL5JI5m[3Kxc4TheIlvNTF?M{T0flI2ODN5OEWx
MM.1S NIXUSZFCeG:ydH;zbZMhSXO|YYm=Ml3INVAx|ryPNXTzN3FbOWh?MojV[YZncWOrZX70cJkheHKndnXueJMhe2:{YX\lcoljNWmwZIXj[YQh[2WubDDk[YF1cCClb33ibY5mKHerdHigcoVkem:|dHH0bY4uOQ>?MXiyOVA{Pzh3MR?=
C6MlzVRZBweHSxc3nzJGF{e2G7NH7mW5k2OM7:TR?=NGfwSms1QGh?NV\FNFNKeHKndnXueJMhfGinIHzvd5Mhd2ZiY3XscEB3cWGkaXzpeJkh[2G3c3XkJIJ6KHC{ZXfu[Y5wdG:wZR?=MlLnNlUxOTN2N{m=
AGSNEfCNllCeG:ydH;zbZMhSXO|YYm=MUm1NO69VQ>?NV\xSY5oOjSqNILIZ2hi[m:uaYPod{DPui2uYYDhZ4hwdmVvaX7keYNm\CClZXzsJIRm[XSqIHHu[EBqdmirYnn0[YQh\3Kxd4ToNE\mVHMzPTByOU[5PC=>
HeLa MoHHRZBweHSxc3nzJGF{e2G7NIC3[mE1OM7:TR?=NID1UmczPGh?NEPTbHNqdmirYnn0d{B1cGViaX7jdoVie2WmIHHwc5B1d3OrczDpcoR2[2WmIHL5JJNqWk6IMUKxM3nHd|I1QTJ6Nki1
THP-1 NWTYbW1rSXCxcITvd4l{KEG|c3H5NXrL[3V2OTEQvF2=MXKxbC=>MnrjdoVlfWOnczDhdI9xfG:|aYOgbY5lfWOnZDDifUBCVEFvU1TUxsA>M4TCVVI1QTJ|NkWz
P815 NXnmUngxSXCxcITvd4l{KEG|c3H5NFvRNYwyODBiwsXNNECxfVYyOmh?M3r2SGROW09?MmXWbY5pcWKrdIOgeolzfXNvaX7keYNm\CCjcH;weI9{cXN?M3KyXFI1QTJ|Mkez
HCT116NX\leHRZSXCxcITvd4l{KEG|c3H5NY\2W3FROjEQvF2=MX2yOIg>NFLn[IZi[nKxZ3H0[ZMhd2ZiVGGtbY5lfWOnZDDhdI9xfG:|aR?=MVeyOFg6ODR2OR?=
SW1116 MlLiRZBweHSxc3nzJGF{e2G7NIj5THQyOCEEtV2=NFjxeYYycA>?NUDZemlkTE2VTx?=MoDpdoV{fHKjaX7zJINmdGxiYYDvdJRwe2m|IHnu[JVk\WRiYomg[4VncXSrbnniJJBtfXNiZHXjbZRi[mmwZR?=MXWyOFg4PDJ6Nh?=
LOVOMVTBdI9xfG:|aYOgRZN{[Xl?M13vVFExKML3TR?=NEfMRpAycA>?MkTTSG1UVw>?MXPy[ZN1emGrboOgZ4VtdCCjcH;weI9{cXNiaX7keYNm\CCkeTDn[YZqfGmwaXKgdIx2eyCmZXPpeIFjcW6nM3G1fFI1QDd2Mki2
SNU449 NF7rO25CeG:ydH;zbZMhSXO|YYm=M4\uOVIx|ryPM2LifFQ5cA>?MoSzSG1UVw>?M2PaOoRm[3KnYYPld{BucVJvNEWxMYlv\HWlZXSgZZBweHSxdHnjNUfDSlVVOjR6NEG2N|g>
Caco-2M1;1bGFxd3C2b4Ppd{BCe3OjeR?=Ml\wOFDjiIoQvF2=NFTWTZM1cA>?NUe5[GZxeHKndnXueJMhW1RvNz3pcoR2[2WmIGrPMVEh[2ijbnfld{BidmRiVFXSJIRzd3B?NYDvOW1pOjR6MkKxPFM>
macrophageNYjlTJltS2WubDDWbYFjcWyrdImgRZN{[Xl?MoDqNE0zODEQvF2=MUKyOIg>MVvpcoR2[2W|IGTOSk0h[W6mIGLpdFMu\GWyZX7k[Y51KG6nY4LvdJRwe2m|IHnuJI1i[3KxcHjh[4U>NUS2TodHOjR5OUm1OlU>
AGS MlPvRZBweHSxc3nzJGF{e2G7NHi3PY4zOM7:TR?=NEHKVVcyOmh?M1:2VGROW09?MU\y[YR2[2W|IITo[UBqdmS3Y4Tpc44hd2ZiYYDvdJRwe2m|IHnuJJJme3CxboPlJJRwKHSqZTDFeG9C[yCocnHjeIlwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?MlyzNlQ4QDl5MEO=
LCC9 MoTkR4VtdCCYaXHibYxqfHliQYPzZZk>NHnUSG0yODEQvF2=MVu1[C=>NEX6U2VjdG:la4OgZ4VtdCCmZXH0bEBqdmS3Y3XkJIJ6KGOxbXLpcoF1cW:wIFyxO{BidmRiY3jsc5JweXWrbnW=NGDvOoIzPDd6NUK1Oi=>
U937 NYXtc3N7dmWlcn;weI9{cXNiQYPzZZk>NWqxe3dHOTEEoN88US=>M{LycFMxyqCvaX6=MmC4bY5lfWOnczDu[YNzd3C2b4Ppd{Bkd22kaX7lJJdqfGhiVF7GMXyyOFc4Ozd3Nh?=
T cellNYOwcoxWS2WubDDwdo9tcW[ncnH0bY9vKGG|c3H5MnP2NE0yODEQvF2=MoLpO|JpMYLJR|UxRTdyIN88UUwhcW6qaXLpeJMh[W62aT3DSFMucW6mdXPl[EBVKGOnbHygdJJwdGmoZYLheIlwdiCrbjDQRm1Eew>?NVLrfodxOjR5Nki3NFc>
HeLa M2GwXmFxd3C2b4Ppd{BCe3OjeR?=NEHScHQ2OM7:TR?=NXHscXRoPzKqNYnGfm94TE2VTx?=NUXXN2xreHKndnXueJMh[XCxcITvd4l{KGmwZIXj[YQh[nliY3;tdI92dmS|wrCx5qCUPQ>?MVSyOFc2PDd6Nh?=
HeLa M4nUR2Fxd3C2b4Ppd{BCe3OjeR?=NGXDXlMyODEQvF2=MX:yOIg>NEexWFN{fXCycnXzd4V{KHKjdHWgc4Yh[2WubDDk[YF1cCCrbnT1Z4VlKGK7IH;2[ZJmgHC{ZYPzbY9vKG:oIFe1PXMhd3JiR{exVkBxOTVyZ3z1[YTDqA>?NUDoc416OjR5MkK0Olg>
IEC-6 MUfBdI9xfG:|aYOgRZN{[Xl?NInjb4syOM7:TR?=NYf1SFloOjSqMlXPdJJmfmWwdIOgWINlSS2rbnT1Z4VlKGOjc4Dhd4UuOyClbHXheoFo\SCjbnSg{tIu[2G2ZX7pckBl\We{YXTheIlwdg>?MU[yOFcyOTV5MR?=
HCT116MnLJRZBweHSxc3nzJGF{e2G7MXuyNO69VQ>?MYCyOIg>NW[zNVlDcW6qaXLpeJMhfGinIHPlcIwh[XCxcITveIlkKGmwZIXj[YQh[nliWVzUNlA2M17C[FI1PzF|OEGy
L02NEXWXWhCeG:ydH;zbZMhSXO|YYm=MW[yNO69VQ>?NH3VbIUycA>?M4DLZZBz\X[nboTzJJRp\SClZXzsJIFxd3C2b4Ppd{BqdmS3Y3XkJIJ6KE2HSGC=MV[yOFcxPjR4MR?=
A375NXzoe5VMSXCxcITvd4l{KEG|c3H5M33XWVIx|ryPNGTRSXkzPGh?NXjse5JtemW4ZYLz[ZMh\GmlaYTybY5wdmViQj3pcoR2[2WmIHHwc5B1d3Orcx?=NXz0SGM6OjR4OUmxNVE>
HDPCM3fVc2Fxd3C2b4Ppd{BCe3OjeR?=M1vmfFUxyrWPNInzfWEzPGh?M4fKT4lvcGmkaYTzJG5QNWmwZIXj[YQh[XCxcITvd4l{NHjtXJIzPDZ|NEW5Ny=>
A549NHrM[HhCeG:ydH;zbZMhSXO|YYm=MnnOOVDDvU1?MlHoNog>M1nVWGROW09?NG[2dndxemW4ZX70d{B1cGViaInwc4RqeGyxaXSgSG5CKGOxboTlcpQheGijc3WgbY5lfWOnZDDifUBk\XCqYXzvZ4hzd22rbh?=NYS3W3luOjR3OEixN|U>
 BV-2NYfsb41lSXCxcITvd4l{KEG|c3H5MUmyNO69VQ>?M4jUSVJpNUH0dXM2e3WycILld5NmeyCXVj3pcoR2[2WmIHPodo9u[XSrbjDlfJRzfXOrb36gZY5lKGSrbHH0bY9vKG:oIITo[UBvfWOuZXHyJIVvfmWub4DlM3XseFI1PTV6MUG4
HT-29 MXfBdI9xfG:|aYOgRZN{[Xl?NWPmNY9iPTEQvF2=NH\zNY01QGh?NULTc3Vw[myxY3vzJJRp\SCjcH;weI9{cXNiaX7keYNm\CCkeTDrZYVueG[ncn;sNXroO3lpOjR3NEmxO|U>
A549MX7BdI9xfG:|aYOgRZN{[Xl?MkjKOe69VQ>?NFPiS5IzPGh?MV3zeZBxemW|c3XzJFZmyqBqQluxNFA1OClvaX7keYNm\CCjcH;weI9{cXQEoB?=NIjwSGUzPDV{OUi3NS=>
MIA-PaCa-2NUnwSldiSXCxcITvd4l{KEG|c3H5NVH0O|ZYOjSqMn:0Zoxw[2u|IHPs[YF3[WenIH;mJINie3Cjc3WtN{BqdmS3Y3XkJIJ6KGKxdHigRU01PDN4NUSgZY5lKHCjY3zpeIF5\Wx?MU[yOFUyODl7Mh?=
Caki-1M1O3ZmFxd3C2b4Ppd{BCe3OjeR?=Ml\JNlDPxE1?NYDrNHB2OWh?NV7nfGJbcW6qaXLpeJMhW0OSLXnu[JVk\WRiYYDvdJRwe2m|M2K1RlI1PTB2Nkix
CLLM2rzZ2Fxd3C2b4Ppd{BCe3OjeR?=NHr5RVUzPc7:TR?=NYThcGN2OWh?Ml;NdIFzfGmjbHz5JIJtd2OtczDNUG4zOjN6LXnu[JVk\WRiY3XscEBieG:ydH;zbZM>NXGwVFUxOjR2Nke2N|Q>
SGC-7901NIXje3lCeG:ydH;zbZMhSXO|YYm=M3jNZlEx|ryPNWjhSFVMOjSqNYj6b4doeHKxbX;0[ZMhfGinIFPHTWkucW6qaXLpeIVlKGOnbHyg[5Jwf3SqIHnuJHNISy15OUCxJINmdGy|MnHPNlQ1PTR2OEi=
k1735MYLBdI9xfG:|aYOgRZN{[Xl?MVmyNQKBkc7:bR?=MoLlOIg>MX\pcohq[mm2c9MgV4FtdW:wZXzsZU1qdmS3Y3XkJIFxd3C2b4Ppdy=>Ml7rNlQ1PTFzMU[=
HaCaT MXjBdI9xfG:|aYOgRZN{[Xl?NGXFbHAyODEQvF2=MWCxbC=>MUHicJVvfHNiVW\CMYlv\HWlZXSgZZBweHSxc3nzJIlvKEijQ3HUJINmdGy|MnezNlQ{PTZ7OUe=
podocytesM4Tic2Fxd3C2b4Ppd{BCe3OjeR?=M2S1NFIxOM7:TR?=MUm2bC=>MmrqbY5pcWKrdIOgZZBweHSxc3nzJIlv\HWlZXSgZpkhOyx2LVTHSS=>MV[yOFM{Pzd5Nx?=
 KBMWnBdI9xfG:|aYOgRZN{[Xl?MYe1NO69VQ>?MljpNlRpNVXPOFgycW6qaXLpeJMhVGmlbz3BMYlv\HWlZXSgZ4F{eGG|ZT2zJIFv\CCSQWLQJIFkfGm4YYTpc44>MVWyOFM{PzR7Mh?=
 HepG2 NH3rbVhCeG:ydH;zbZMhSXO|YYm=NF7pSHUyOM7:TR?=NV;MWWZIOjSqNH\OdVlz\WS3Y3XzJJZqdWWwdHnuJINt\WG4YXflJINifXOnZDDifUBNWFN?MlvTNlQ{OjV6MU[=
fetal rat lung fibroblasts MXLLbY5ie2ViQYPzZZk>MV24NO69VcLiMXKxbC=>NX\mTWJicW6qaXLpeJMhS2G|cHHz[U0{KGGldHn2bZR6yqB?NWnOO3J4OjR|MUSxN|U>
PDL fibroblastsMXvLbY5ie2ViQYPzZZk>MnzEPFDPxE4EoB?=MlzWNYg>MUXpcohq[mm2czDDZZNx[XOnLUOgZYN1cX[rdIpCpC=>NWG4bVRPOjR|MUSxN|U>
MB49Mk\QRZBweHSxc3nzJGF{e2G7M4PHXVIx|ryPNHf0Z4sycA>?MWLy[ZZmenOnczDDUU1qdmS3Y3XkJINmdGxiZHXheIg>MVmyOFI5OjR|Mx?=
5637MUDBdI9xfG:|aYOgRZN{[Xl?NHnz[HMzOM7:TR?=MonyNYg>NFHzOndz\X[ncoPld{BEVS2rbnT1Z4VlKGOnbHyg[IVifGh?NF:0U4MzPDJ6MkSzNy=>
A549 MVjBdI9xfG:|aYOgRZN{[Xl?NF\hNJgyODEQvF2=NWHaTnN4PDiqNHvyTGh{fXCycnXzd4V{KHSqZTDhdI9xfG:|aYOgZ4F2e2WmIHL5JJBqeGW{aX7lxsA>NI\0WnUzPDJ5MkKwNS=>
MCC-2MmfSRZBweHSxc3nzJGF{e2G7NFHQflUzOCEQvF2=NUjKXotjPmh?MoC3SG1UVw>?MY\icI9kc3NiaX7keYNm\CCkeTDzeIF2em:|cH;ybY5mKGGyb4D0c5NqeyClZXzsJIRm[XSqNWHJSHh2OjR{NkK2OVg>
ADFNXLiOJhwSXCxcITvd4l{KEG|c3H5MVe0NO69VQ>?M3fiWlZpM37qTYlvcGmkaYTzJIFxd3C2b4Ppd{BqdmS3Y3XkJIJ6KGOqZX3veIhmemGyeTDwcJV{KFqwQ3yyNX61VGNUOjR{MkiyN|I>
 U373 MnT2RZBweHSxc3nzJGF{e2G7MV[0NO69VQ>?MYm2bC=>M2Lae4lvcGmkaYTzJIFxd3C2b4Ppd{BqdmS3Y3XkJIJ6KGOqZX3veIhmemGyeTDwcJV{KFqwQ3yyMV6yOFIzQDJ|Mh?=
RKO-HIPK2iNVq5O4JoSXCxcITvd4l{KEG|c3H5MmX5OFDPxE1?Mk\qOog>NV7Wdo9FcW6qaXLpeJMh[XCxcITvd4l{KGmwZIXj[YQh[nliY3jlcY91cGW{YYD5JJBtfXNiWn7DcFI>MWOyOFIzQDJ|Mh?=
HEC-1BMmjoRZBweHSxc3nzJGF{e2G7M1HRb|Ix|ryPMorYNYg>NYLHfJBOemWmdXPld{BVWC2rbnT1Z4VlKGGyb4D0c5Nqe8LiY3HzdIF{\S1|IHHu[EBk[XOyYYPlMVk>M1nmXlI1OjF|M{W4
4T1M2nGZWNmdGxiVnnhZoltcXS7IFHzd4F6NYi0[GN5Oi53LUGw{txOMlHwOIg>MkL3SG1UVw>?M4jXZpJme2O3ZYOgeIhmKGO7dH;0c5hq[2m2eTDv[kA1XDFiY3XscJMhcW6mdXPl[EBjgSCVUFTUJIlvKGFiY3;uZ4VvfHKjdHnvckBl\XCnbnTlcpQhdWGwbnXyM3LucVI1OjB4MU[x
OS MmX3RZBweHSxc3nzJGF{e2G7NFy1VYozOM7:TR?=M1uyZ|RpM2L4folvcGmkaYTzJJRp\SClZXzsJIRm[XSqIHPheZNm\CCkeTDQSHQ>NVT4e2xWOjR{MES5N|c>
RPEM{LxdGFxd3C2b4Ppd{BCe3OjeR?=M{fM[FExOM7:TR?=MkDXOFhpNY[3b4dYeGG{dHnhcIx6KGmwaHnibZR{KHSqZTDjZYxx[WmwLUGgZY5lKC1{IHHjeIl3[XSrb36gZZMhf2WubDDhd{B1cGViY3HzdIF{\SCjY4TpeoF1cW:wMV[yOFIxOjB3Mh?=
UD29aM3jDNGFxd3C2b4Ppd{BCe3OjeR?=MnfvOVDPxE1?MX[yOIg>Ml\SbY5pcWKrdIOgeIhmKGOnbHyg[IVifGhiY3H1d4VlKGK7IF7VWFM>MlXSNlQyQTB3N{S=
SH-SY5Y NFTpRodCeG:ydH;zbZMhSXO|YYm=NVS1dW1POTEQvF2=NXjwbFF1OjSqM37seoF1fGWwdXH0[ZMh[2G|cHHz[UBi[3SrdnH0bY9vKGGwZDDj[YxtKGSnYYToJIlv\HWlZXSgZpkhUE6HLULESy=>NV7EV3hMOjRzNEW0OlM>
HeLa NEjiS5VCeG:ydH;zbZMhSXO|YYm=MWGxNE8zOM7:TR?=M2Lje|I1cA>?M3LmZolvcGmkaYTzJJRp\SCjY4Tpeol1gSCxZjD0bIUhdWGsb4LpeJkhd2ZidHjlJI1mdWKncoOgc4YhfGinIHPhd5Bie2VvZnHtbYx6NUmySGp5OjRzM{eyOlY>
SCCVII NFvH[HRCeG:ydH;zbZMhSXO|YYm=MlHqNlXPxE1?NUDycXU4OWh?NW\5W|l6cW6qaXLpeJMhfGinIHPlcIwhc2mubHnu[{Bi\nSncjDkZZNifGmwaXK=MnTTNlQyOjZ2NkS=
RAW 264.7MV;BdI9xfG:|aYOgRZN{[Xl?NVHCUY9GOjEQvF2=NEnaN5UyQGh?M2\nO4lv[3KnYYPld{BNSzNvSVmv{tIu[WO2aX6gdoF1cW9iY3;tdIFz\WRidH:gSWNVXi2PT2OgeJJm[XSvZX70JI9vdHl?M2GxXFI1OTF4N{C3
A549 M1O3OGFxd3C2b4Ppd{BCe3OjeR?=NGfFR3EzNjYQvF2=M1;vW|I1cA>?MojW[IVkemWjc3XzJI9zcWSxbnnuMYlv\HWlZXSgZZV1d3CqYXf5JIF{KHenbHygZY5lKEyxc4Ogc4Yh|pURiH2gZYx{dyCxY3P1dpJm\CCmdYLpcoch[XW2b4DoZYdq[yCycn;j[ZN{MUiyOFExOjV{Mh?=
UM-SCC-10A NEm1RZdCeG:ydH;zbZMhSXO|YYm=NGjkfHg2OML3TR?=MVqybC=>M2f1VZJm\HWlZYOgZZBweHSxc3nzJIlv\HWlZXSgZpkhcGmpaD3kc5NmKGm|b3HsZY51d2yjY4TvcoU>Mn;rNlQxQTh5NUO=
BGC-823MmnnRZBweHSxc3nzJGF{e2G7NEnwcXMyOCEQvF2=MlHPNlRpMVny[YR2[2W|IITleJJidmS{aX7lMYlv\HWlZXSgZZBweHSxc3nzxsA>NX\4VIVXOjRyOUi1NVE>
Nalm-6 NGPpTXlCeG:ydH;zbZMhSXO|YYm=NIPjVVQzOM7:TR?=NGq5WHE1cA>?MU\pcohq[mm2czDjZZNx[XOnLUigZY5lKGOjc4Dhd4UuOyCjY4TpeoF1cW:wIHHu[EBRSVKSLUGgZ4xm[X[jZ3W=MUWyOFA{QTl4Nx?=
KHOS MV3BdI9xfG:|aYOgRZN{[Xl?NUi0RlEyPDEQvF2=MY[yOIg>NWHmcHpP[myxY3vzJJRp\SCrbnPy[YF{\WRiY3zlZZZi\2Vib3[gZ4F{eGG|ZT2zJIFv\CCSQWLQJIlv\HWlZXSgZpkhSkKPRERCpC=>M2fCS|I1ODJ3M{[x
G292NIjKfpRCeG:ydH;zbZMhSXO|YYm=MV[0NO69VQ>?M{PMb|I1cA>?MUficI9kc3NidHjlJIlv[3KnYYPl[EBkdGWjdnHn[UBw\iClYYPwZZNmNTNiYX7kJHBCWlBiaX7keYNm\CCkeTDCRm1FO8LiMkT2NlQxOjV|NkG=
MG-63MXPBdI9xfG:|aYOgRZN{[Xl?NXPDbnFpPDEQvF2=NIXRU4UzPGh?MWnicI9kc3NidHjlJIlv[3KnYYPl[EBkdGWjdnHn[UBw\iClYYPwZZNmNTNiYX7kJHBCWlBiaX7keYNm\CCkeTDCRm1FO8LiNGXF[mIzPDB{NUO2NS=>
EBV-transformed B cellsMYXBdI9xfG:|aYOgRZN{[Xl?MonGNlDPxE1?Mlu3Nog>MWfEUXNQMXvicI9kc3NiYX70bU1ETDhyIHHu[EBidnSrLVPEPFYh[W62aXLv[JkucW6mdXPl[EBieG:ydH;zbZM>NELVPJozPDByOE[yPC=>
IM-9 BM2jpO2Fxd3C2b4Ppd{BCe3OjeR?=NXfaOnk4OjEQvF2=MnXrNog>NFr5[olFVVORMWTicI9kc3NiYX70bU1ETDhyIHHu[EBidnSrLVPEPFYh[W62aXLv[JkucW6mdXPl[EBieG:ydH;zbZM>NFf0dGQzPDByOE[yPC=>
CNE1NUjjVnhKSXCxcITvd4l{KEG|c3H5Ml74NlDPxE1?NU\lXnhJPDiqNHG2eXpjdG:la4OgUGsuSS2rbnT1Z4VlKGGyb4D0c5Nqew>?NH;2dowzOzl6NUCyPS=>
CNE2MV\BdI9xfG:|aYOgRZN{[Xl?M3K1OFIx|ryPNYG4fIxXPDiqM4TJNIJtd2OtczDMT{1CNWmwZIXj[YQh[XCxcITvd4l{NUfxb|dzOjN7OEWwNlk>
HL-60Mlq5RZBweHSxc3nzJGF{e2G7M373cFUxyrWPNY\MSWQ5OWh?M3PDRWROW09?MmjXbY5pcWKrdIOgZZBweHSxc3nzJIlv\HWlZXSgZpkhSkFzNEW=NG\RZmQzOzl2OEe1NS=>
L929M3XYOGFxd3C2b4Ppd{BCe3OjeR?=Mn7FNU4zPeLCk{ZCpO69VcLiMX2yOIg>NY\FS3lH[XWpbXXueJMhXE6IzsGtbY5lfWOnZDDu[YNzd3C2b4Ppd{BidmRiYYX0c5Bp[We7NV;1fnNrOjN7NEG3Olk>
JurkatNFG0SIlE\WyuIG\pZYJqdGm2eTDBd5NigQ>?MmfrNu69VQ>?Mmr6OIg>MnHYdoV3\XK|ZYOg[5Jwf3SqIHnubIljcXSrb36gZY5lKM7{LXPheIVvcW5iZHXjdoVie2ViYomgTHMuSVODNHH0UGwzOzh7NkC2NS=>
RAW264.7 MX\BdI9xfG:|aYOgRZN{[Xl?MkfrNVAh|ryPMUSyOIg>NF3ueGxl\WO{ZXHz[ZMhfGinIHHwc5B1d3OrczDpcoR2[2WmIHL5JGdCNFjqdoMzOzh{MEKwNy=>
A431 MXXLbY5ie2ViQYPzZZk>MXq0NO69VQ>?MWiybC=>Mn;TZoxw[2u|IH\pd4V1cW5vaX7keYNm\CClbHXheoFo\SCxZjDjZZNx[XOnczDhcoQhWEGUUB?=NEfGbo4zOzhyMEC1PC=>
JurkatMnTmR4VtdCCYaXHibYxqfHliQYPzZZk>M4fWU|I2NTFyMN88US=>MUi2bC=>NHfhbYZqdmirYnn0d{B7NU[DLVPNT{1qdmS3Y3XkJINmdGxiZHXheIg>M{frN|I{QTN|NUOy
COS-7 MVvGeY5kfGmxbjDBd5NigQ>?MnjaOVDDvU1?M4LQ[VI1cA>?NELWTI1i\m[nY4TzJJRp\SCycn;j[ZN{cW6pIH;mJGFVVjG|IIfpeIgheG:ueWGgeJJi[3S|Mkf2NlM6OzN{MEi=
CAL27NVWxOJc6SXCxcITvd4l{KEG|c3H5M3rX[|ExKM7:TR?=MnTENog>NVHwclh5e3WycILld5NmeyCFdYKtUnB{NXKnZIXj[YQhfmmjYnnsbZR6KGK7IIXwJJRwKDlyJR?=NVnwZWFMOjN7MUezPVY>
THP-1 M4PMUWFxd3C2b4Ppd{BCe3OjeR?=NVP1OFlMOTBvNUFOwG0>MkXJNog>MWTpcohq[mm2czDhdI9xfG:|aYOgbY5lfWOnZDDifUB1emmydH;sbYRmMUKyN|kxODJ7OR?=
K562NH:3O3BCeG:ydH;zbZMhSXO|YYm=MnfnNlDPxE1?NUnGdJo{PDiqM2XhRYlvcGmkaYTzJIFxd3C2b4Ppd{BqdmS3Y3XkJIJ6KDRvTWW=NF7SdokzOzh5NkiyOi=>
HL-60M4TmR2Fxd3C2b4Ppd{BCe3OjeR?=NIH2OoYyODEQvF2=NFe5cnczPGh?M3PyNIlvcGmkaYTzJIFxd3C2b4Ppd{BqdmS3Y3XkJIJ6KGGkaXX0ZY5mKGSrdHXydIVv\XQEoB?=Mn;qNlM5PjV5N{i=
HeLa Mn3yRZBweHSxc3nzJGF{e2G7NHWzNFEzOM7:TR?=MVmybC=>NHG3fZNqdmirYnn0d{BFVU2SIHnu[JVk\WRiYYDvdJRwe2m|MlrYNlM5PjN7Nk[=
U251NIXSco9CeG:ydH;zbZMhSXO|YYm=NYf6d5MyOjEQvF2=MoLDNlRpMVnpcohq[mm2czDjZZN1cWOrbjDpcoR2[2WmIFeyM20heGijc3WgZZJz\XO2IHHu[EBieG:ydH;zbZM>MlPlNlM5OTZ6MU[=
HL-60NIHGeoJCeG:ydH;zbZMhSXO|YYm=NFTQ[oc2OML3TR?=NWT0[Zd5PGh?M3v5eoJtd2OtczD0bIUh[2ynYY\h[4Uhd2ZiY3HzdIF{\S1|LDCtPUwh[W6mIGDBVnAhcW6mdXPl[EBjgSB4cx?=NWD0WIFIOjN6MES3NFY>
Ec-109M3nwd2Fxd3C2b4Ppd{BCe3OjeR?=NFPFbXgyOCEQvF2=NX;Ge5A2PDiqMUTy[ZBz\XO|ZYOgVGUudWWmaXH0[YQhTWNvMUC5JINmdGxiYYDvdJRwe2m|NGHSd2MzOzd6Mk[0NS=>
RKOM1ftWWNmdGxiVnnhZoltcXS7IFHzd4F6MUOxNEDPxE1?NXvJfoxGOjSqMWXpcohq[mm2czD0bIUh\GWlcnXhd4Uhd2ZiY3XscEB3cWGkaXzpeJkh[2G3c3XkJIJ6KESDQh?=M3ruXFI{PzV6ME[0
T98GNETTZmlE\WyuIG\pZYJqdGm2eTDBd5NigQ>?NFnVd5AyNTFyMN88US=>NFLqPYMzPGh?NX7sVZN3cW2ycn;2[ZMh[2WubDD2bYFjcWyrdImgZ491emWjdH3lcpQhf2m2aDDUVy=>MWqyN|c3QTJ5NR?=
JurkatMWPD[YxtKF[rYXLpcIl1gSCDc4PhfS=>NYK5dIY{OTByLUKwNO69VQ>?M3njbVI1cA>?M{TLR4lvcGmkaYTzJGhiSTRiaX7keYNmeyCjcH;weI9{cXNiZHXw[Y5l\W62IH;mJINwdmOnboTyZZRqd28EoB?=NHTw[mUzOzd|MkS4NS=>
Molt-3 M3jNT2Fxd3C2b4Ppd{BCe3OjeR?=NFTkU|E2OM7:TR?=NYrrRpdzOmh?NGmxPYNz\WS3Y3XzJI1mdGG2b37pck1qdmS3Y3XkJIFxd3C2b4Ppdy=>M4G5VVI{PzJ3MEGz
hMSC12M3\RUWFxd3C2b4Ppd{BCe3OjeR?=NFrFWoYyODEQvF2=NFjiR4g1\A>?MWHpcohq[mm2czDvd5Rmd2enbnnjJIN2dHS3cnWtbY5lfWOnZDDj[YxtKGSnYYToJIFv\CClYXzjbYZq[2G2aX;uMoPtNlM3PTd6MkK=
HM7 MnvYRZBweHSxc3nzJGF{e2G7Ml\lNlDPxE4EoB?=NELXeGcycA>?MofTZoxw[2u|IHHwbYN2dGG{ZX6gRUBi[2W2YYTlMYlv\HWlZXSgZ4F{eGG|ZT2zJIFkfGm4YYTpc44h[W6mIGDBVnAh[2ynYY\h[4U>M1LLO|I{PTh|NEGy
Hep-2 M4LSNGFxd3C2b4Ppd{BCe3OjeR?=MnflNlDPxE4EoB?=MnqwNlRpNG\6UYhFVVORM2TjcIFtdGW4aXH0[ZMhfGinIHTlZ5Jm[XOnIH;mJINmdGxidnnhZoltcXS7IHnu[JVk\WRiYomgd4ltcWKrbnnuMXKyN|U5ODB|Mh?=
HSCsMUTBdI9xfG:|aYOgRZN{[Xl?NVzoZWZYPTEQvF2=NUXrZWVSOjSqMVTEUXNQNEPWNlhqdmirYnn0d{BvcWyxdHnubYIucW6mdXPl[EBFVkFiZHHtZYdmKGmwZHnjZZRm\CCkeTDQRXJRKGOuZXH2ZYdmNIHGXG0zOzR7OUi3OC=>
HL-60 M4jjSWN6fG:2b4jpZ4l1gSCDc4PhfS=>M3\PO|Ix|ryPwrC=MViyOIg>NIjmfWFz\WS3Y3XzJJRp\SCleYTveI95cWNiZX\m[YN1KG:oIFXyfVU>NVXDeJJROjN2OUS0PFA>
HAMnrFRZBweHSxc3nzJGF{e2G7NYPrZ3FzPTEQvF2=MlftNlRpM2\vd5N2eHC{ZYPz[ZMhfGinIHPs[YF3[WenIH;mJHBCWlBiYX7kJINie3Cjc3WtN{whNTduIHHu[EAuQSCrbnT1Z4VlKGK7IHLvdpRmgm:vaXKvV2FJSQ>?MoX5NlM1PzV7NU[=
C666-1NYrnRpNISXCxcITvd4l{KEG|c3H5M3HROVUx|ryPMXqyOIg>NFzkTZF{fXCycnXzd4V{KHSqZTDjcIVifmGpZTDv[kBRSVKSIHHu[EBk[XOyYYPlMVMtKC15LDDhcoQhNTliaX7keYNm\CCkeTDic5J1\XqxbXniM3NCUEF?MXyyN|Q4PTl3Nh?=
Hepa1-6NEHy[GZCeG:ydH;zbZMhSXO|YYm=Mo\oOVDPxE1?MVGybC=>M3jGZ4lvcGmkaYTzJIN2emO3bXnuJIFv\CC{ZYP2[ZJifHKxbD3pcoR2[2WmIHHwc5B1d3Orcx?=MXyyN|Q1Pjd3Mx?=
PLC/PRF/5cNIn4ZWVCeG:ydH;zbZMhSXO|YYm=MV21NO69VQ>?MW[xbC=>NEjhWmtxemW4ZX70d{BieG:ydH;zbZMhfHKrZ3fldoVlKGK7IFPJUi=>M4fBUFI{PDN6OEK0
HCT116NH[wR|JCeG:ydH;zbZMhSXO|YYm=M3nnXlExOM7:TR?=MkWyNU42cA>?NF[5TlRqdmirYnn0d{BQey2rbnT1Z4VlKGOnbHyg[IVifGh?MXSyN|c1PDN3Mx?=
HCECNXPGUG1[TnWwY4Tpc44hSXO|YYm=Mmq0OVDPxE1?M3qwWFczcA>?MlLGSG1UVw>?NVvIUGM4emW|dH;y[ZMhd2ZidHjlJI5wem2jbDDIR2VEKHCqZX7veJlx\Q>?M4XjRlI{PzR{MEGx
Primary rat cerebral cortical neuronsNGnTOmdCeG:ydH;zbZMhSXO|YYm=MYWxNFDPxE1?NIDvTHUycA>?MlHHdJJmfmWwdIOgR4QucW6mdXPl[EBieG:ydH;zbZMh[W6mIHPlcIwh\GWjdHi=MYGyN|c1OTNzNx?=
MDA-MB-231 M3e4[2Fxd3C2b4Ppd{BCe3OjeR?=MnviNlXPxE1?Ml:yNlRpMX3hZpJw\2G2ZYOgZ5l1d3SxeHnjbZR6KGGwZDDjcIVifmGpZTDv[kBk[XOyYYPlMVMh[W6mIGDBVnAhcW6mdXPl[EBjgSCUZ{O=NXm5eFh6OjV|M{e1OFQ>
NLRP3-Tet-on-MC/9 MWPBdI9xfG:|aYOgRZN{[Xl?M{HHflExNTRyzszNMk\pNVJpMYjheJRmdnWjdHXzJJRp\SClZXzsJIRm[XSqIHPheZNm\CCkeTDDRXBUNWG|c3;jbYF1\WRiTlzSVFMhdXW2YX70d{BqdiC2aHWgWIV1NW:wIIP5d5RmdQ>?MXOyN|cxOzN6OR?=
KNS42 NWTWemo5SXCxcITvd4l{KEG|c3H5MnrZOVDPxE1?NVK2VGhvOWh?NUjHZ3hFemWmdXPld{Bk\WyuIHTlZZRpKGGwZDDjc41xdGW2ZXz5JIFjd2yrc3jl[EBk[XOyYYPlJFMwPyCjY4Tpeol1gSCrbjDy[ZNxd26|ZTD0c{BCSlRvMk[zM|JFTy:vZYTmc5JucW5iY3;tZolv[XSrb36=NHTWWnYzOzZ7MUG0OS=>
MCF-7 Mkm4RZBweHSxc3nzJGF{e2G7M1HQRVIx|ryPwrC=Mn\NO|JpNVnLVYFZcW6qaXLpeJMh\XG3b3ytJIFv\CB2LV;IWE1u\WSrYYTl[EBieG:ydH;zbZM>MonwNlM3PzV4NEO=
hCMEC/D3 NHv2W2dCeG:ydH;zbZMhSXO|YYm=M2fmclI2|ryPM1rtOFczcA>?MkPRdoVlfWOnczDMeJhCKGmwZIXj[YQh[XCxcITvd4l{M4XwOVI{PjZ3MUm4
JurkatM3W3[GFxd3C2b4Ppd{BCe3OjeR?=NXvneVFWOTJwNT21NO69VQ>?MX2xbC=>NVroclE{\G:|ZTDk[ZBmdmSnboTsfUB{fXCycnXzd4V{KFOSSD3pcoR2[2WmIGDhdk01KGOuZXH2ZYdmNCCSQWLQJINt\WG4YXflMEBFVkFiZoLh[41mdnSjdHnvckwh[W6mIHzvd5Mhd2ZidnnhZoltcXS7NWnLenNFOjN2NEK5O|Y>
CNE-1NIjnNHlCeG:ydH;zbZMhSXO|YYm=MWKyNO69VcLiMnOzNlRpNYnXRWl{cW6qaXLpeJMhWkGGMECxMYlv\HWlZXSgZ4VtdCCmZXH0bC=>MlrDNlM1OjZ6NUC=
HONE-1NYrYc5E2SXCxcITvd4l{KEG|c3H5Mk\wNlDPxE4EoB?=MVWyOIg>M3P0NYlvcGmkaYTzJHJCTDByMT3pcoR2[2WmIHPlcIwh\GWjdHi=MlvGNlM1OjZ6NUC=
astrocytes cellMnvyRZBweHSxc3nzJGF{e2G7M2nVd|Qx|ryPMlv5Oog>NGHhZVVz\WS3Y3XzJIViemy7IHHwc5B1d3OrczDpcoR2[2WmIHL5JJN1[XW{b4Pwc5JqdmV?MlO5NlM1OTF5N{i=
U-937NH;BNVZCeG:ydH;zbZMhSXO|YYm=M3HMWVEx|ryPNHfBZ5g{OG2rbh?=MnLXdJJmfmWwdIOgWG5HNWmwZIXj[YQhdmWlcn;weI9{cXN?M4HablI{PDFyN{S4
MDA-MB-231M3;yTWFxd3C2b4Ppd{BCe3OjeR?=MYCxNFDPxE1?Mkm0NYg>MWrpcohq[mm2czDz[Y5{cXSrenH0bY9vKHSxIGTSRWlNKHWyb36gUXRFUCCmb4fuMZJm\3WuYYTpc44>NF3N[pozOzRyOESyPS=>
HeLa MWXBdI9xfG:|aYOgRZN{[Xl?MX:xNFDPxE1?Ml\TNog>M4PNboJtd2OtczDKVnMuOTViSX7keYNmeyCDcH;weI91cWNiQ3XscEBF\WG2aB?=NGDC[3czOzN2NEC0OS=>
Ec109NVPLZnlCSXCxcITvd4l{KEG|c3H5NWDje3JsOTEQvF2=MXO2bC=>MYDicI9kc3NiYYDvdJRwfGmlIHPvcYJqdmG2aX;uJI9nKFSjdD3TcYFkVjdiYX7kJJJi\GmjdHnvci=>M3rFVFI{OzN6NU[4
H460 NIXXTVhCeG:ydH;zbZMhSXO|YYm=NFrn[FAyOM7:TR?=NVfuTFc4Pmh?Mk\lZoxw[2u|IHHwc5B1d3SrYzDjc41jcW6jdHnvckBw\iCWYYStV41i[055IHHu[EBz[WSrYYTpc44>MUCyN|M{QDV4OB?=
HeLa M3LLc2Fxd3C2b4Ppd{BCe3OjeR?=NV3xe3Q1PTEQvF2=NFfNT2kyNjWqMXLhZpJw\2G2ZYRCpGNpdGGveXTpZU1qdmS3Y3XkJIFxd3C2b4Ppdy=>M1TNUlI{OzB|OEC0
SK-HEP1NWTFdpRrSXCxcITvd4l{KEG|c3H5M2PH[|ExOM7:TR?=MVuxbC=>Mkf6bY5pcWKrdIOgR5JVOSCjY4TpeoF1\WRiY3HzdIF{\S1|LDCtO{whNThuID25MEBidmRicH;sfUhCTFBvcnnic5NmMSCyb3z5cYVz[XOnMUSyN|MxOjZ3MB?=
QGY7701MkThRZBweHSxc3nzJGF{e2G7MWSyOe69VQ>?NX;TTmpQOS53aB?=M2\xNYlvcGmkaYTzJIFk[3WvdXzheIlwdiCxZjDzeYIuTzFicHjhd4UhcW6mdXPl[EBjgSCGT2igL{ByfWW{Y3X0bY4>M3vufFI{OjRyME[x
HepG2MknlRZBweHSxc3nzJGF{e2G7NXKzUmh7OjEQvF2=NYjrcYlEOzCvaX6=MlvsbY5pcWKrdIOgeIhmKGWwaHHuZ4VlKGOnbHyg[IVifGhiYomgZ49u[mmwZXSgeJJm[XSvZX70JI9nKGGyaXflcolvKGGwZDDUVmFKVA>?M1ruUlI{OjJ2MkO5
U87 M1j2N2Fxd3C2b4Ppd{BCe3OjeR?=MoP5NlXPxE1?M4juTVJpMWXk[YNz\WG|ZYOgbZNwdGmzdXnybZRq\2WwaX6gLGlUVClvaX7keYNm\CCjcH;weI91cWNiY3XscEBl\WG2aDygZpV1KG6xdDDu[YNzd3SrYzDj[YxtKGSnYYToMX2yN|IzQTZ{Nh?=
HSC-2MY\BdI9xfG:|aYOgRZN{[Xl?NV3jeI01OjVxNUFOwG0>MnW1NYg>MVTpcohq[mm2czDTUk0{QC2rbnT1Z4VlKGO7dH;0c5hq[2m2eR?=M4j1VVI{OTV3MkS4
HSC-4M3TtR2Fxd3C2b4Ppd{BCe3OjeR?=NHz0d|MzPS93MN88US=>NHj1d24ycA>?NH\jPJpqdmirYnn0d{BUVi1|OD3pcoR2[2WmIHP5eI91d3irY3n0fS=>NXH3fZFuOjNzNUWyOFg>
CL-1MmnDRZBweHSxc3nzJGF{e2G7MoPWNlDPxE1?Mnv3NYg>M1PZ[IJtd2OtczDPVFQ1QSCrbnT1Z4VlKGOnbHyg[IVifGh?NYLieoRxOjNzM{G3PFI>
MELNIX3bXpCeG:ydH;zbZMhSXO|YYm=NEfwclczOM7:TR?=Mm\YNlRpNWPRR|I5TE2VTx?=NV\aTG41cW2yYXny[ZMhWDK[Nz3pcoR2[2WmIF3FUEBk\WyuIHHwc5B1d3Orcx?=NYPYU3FSOjNyMUS4PFc>
Bel-7402 NXPt[ZdLS2G|cHHz[UBC[3SrdnH0bY9vKEG|c3H5NXnENpU6PTEQvF2=NWfKWlFlOmh?NEHjOI1qdmirYnn0d{BRS0VvaX7keYNm\CCjbn;pb4l{MkLqNlMxODh5NEK=
Eca-109MoXNRZBweHSxc3nzJGF{e2G7M1\1blI2|ryPMYizNI1qdg>?M2HWbolvcGmkaYTzJGJLNUJzMT3pcoR2[2WmIHPlcIwh\GWjdHi=NGKzcXMzOzB5Nkm2Oy=>
MELNUDpTGE3SXCxcITvd4l{KEG|c3H5MXeyNO69VQ>?NIXNXI4ycA>?NInmc25FVVORM4rFbolueGGrcnXzJHAzYDdvaX7keYNm\CCPRVygZ4VtdCCjcH;weI9{cXN?M1jIcVI{ODF2OEi3
Bel-7402 NUToZ4Y3SXCxcITvd4l{KEG|c3H5NH\ac|U2OM7:TR?=MmPTNog>NGnCOHhqdmirYnn0d{BRS0VvaX7keYNm\CCjbn;pb4l{NUDsc281OjNyMEi3OFI>
L929MYLGeY5kfGmxbjDBd5NigQ>?NFK3O4MzNjYQvF2=M2q1OFFpNVfp[lVpcW6lcnXhd4V{KFKLUEGg[ZhxemW|c3nvckBidmRiZYjhZ4Vz[mG2ZXSgWG5H|rFvaX7keYNm\CCvaYTvZ4hwdmS{aXHsJIR6e2[3bnP0bY9vKGGwZDDSU3MheHKxZIXjeIlwdg>?MlfsNlMxODB3MUi=
RCC MUfD[YxtKF[rYXLpcIl1gSCDc4PhfS=>NV71e4JqOTByzszNNEHmT|gzPGh?NIrZT4pz\WOxdnXy[ZMhfGinII\pZYJqdGm2eTDv[kBk\WyuczDlfJBwe2WmIITvJFE2\C2SR1qyMXuyNlk6OTR7NB?=
NB2a/d1NXHyV2tUSXCxcITvd4l{KEG|c3H5M4W0clExOM7:TR?=MlzQO|JpM17FdYF1fGWwdXH0[ZMhe3SjdYLvd5BwemmwZT3pcoR2[2WmIHPhd5Bie2ViYXP0bZZqfHluIGDBVnAtKGGwZDD0ZZUh[2ynYY\h[4U>NHvYVXgzOjl6OEW0NS=>
T cellNYLzeW5zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH7SRWUzPS1zMEFOwG0>M1zlcVI1cA>?M4qxS4Rwe2VvZHXw[Y5l\W62bImgbY5pcWKrdHXkJHQh[2WubDDwdo9tcW[ncnH0bY9vKG2nZHnheIVlKHSqcn;1[4ghfGinIHPvMZN1cW23bHH0bY9vKHerdHigZY51cS2FREOgZY5lKGGwdHmtR2QzQA>?MYqyNlk5OjV|OB?=
K562NYHGVphtSXCxcITvd4l{KEG|c3H5Ml;RNVAx|ryPNUH3ZWwyOWh?MV\icI9kc3NiQXLuc4Jifmm|Y4XtxsBHNWmwZIXj[YQh[XCxcITvd4l{NIm3UIkzOjl5MkO3Ni=>
Jurkat M3Tjd2Fxd3C2b4Ppd{BCe3OjeR?=NYfIOGx5PDEQvF2=MnHyNYg>NH;sc4Ni[m:uaYPo[ZMhTmG|TD3pcoR2[2WmIHPhd5Bie2ViYXP0bZZifGmxbjDhcoQh[2WubDDk[YF1cA>?M1L5SlIzQTR{N{O4
BGC-823M{GxcWFxd3C2b4Ppd{BCe3OjeR?=M4rEdFExOM7:TR?=MkW1NYg>Ml7QdIFzfGmjbHz5JJJme2O3ZYOgZ4VtdHNiYXfhbY5{fCCmYX3h[4Uhd2ZiZHHp[JpmcW5?MWWyNlkzPjV2NR?=
Hep3BMVHBdI9xfG:|aYOgRZN{[Xl?M{C0OVUx|ryPM3LIVFFpM2Ll[oJtd2OtczDhdI9xfG:|aYOgbY5lfWOnZDDifUBJTUeFcx?=NFr2fGszOjl{M{G1OC=>
LLC-PK1MVHBdI9xfG:|aYOgRZN{[Xl?NH7F[mczOM7:TR?=MXyxbC=>NFPKemRxemW4ZX70d{BkcXOybHH0bY4ucW6mdXPl[EBl\We{YXTheIlwdiCxZjDBeIc2NCCkZXPsbY4uOSxiYX7kJGF1\zF{IIDyc5RmcW6|NUXXe|lvOjJ6OU[wN|c>
A549M{ewZ2Fxd3C2b4Ppd{BCe3OjeR?=M3zVW|Ux|ryPNVHXV3MyOWh?M3\adYJtd2OtczD0bIUhSkGLLXnu[JVk\WRiYYDvdJRwe2m|wrC=NIDMNXIzOjh6N{KxOS=>
SGC-7901 NHv5Z|ZCeG:ydH;zbZMhSXO|YYm=M4fJdFEx|ryPNF71VXAzPGh?MXrpcohq[mm2czFOtkzPui2maX3leIh6dGGlconsd4hqc2:waX6tbY5lfWOnZDDhdI9xfG:|aYRCpC=>NEj4XJEzOjh2OEW5Oy=>
DM6Ml;oRZBweHSxc3nzJGF{e2G7M2\hb|ExOM7:TR?=NEHxNFA4Omh?MYHicI9kc3NiYn;0bEBGOkZvMTDhcoQhTTKIdIKtcYVlcWG2ZXSgZ5l1d3SxeHnjbZR6NEH4N2kzOjh{NUOyPC=>
MCF-7, MDA-MB-468, Caco-2NXzJVoQ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFnNZnY2OM7:TR?=NGThWY41QGh?MkHpbY5pcWKrdIOgeIhmKGOnbHyg[5Jwf3SqIHnubIljcXSrb36gbY5lfWOnZDDifUB{[XCxbnnuNFeyT|kzOjhyMEm2PC=>
A2750 NVLzU25USXCxcITvd4l{KEG|c3H5MnzDNlDPxE1?M4LBdFJpNGXGNZFFVVORMXvicI9kc3NiY3HzdIF{\SClbHXheoFo\SCmdYLpcochcGWuZX7hcIlvKHS{ZXH0cYVvfCCjbnSgdoVlfWOnczDheZRweGijZ3njJINmdGxiZHXheIg>MUOyNlc5PDN4Mx?=
U87 M1nacWFxd3C2b4Ppd{BCe3OjeR?=M4LGUlIx|ryPMk\iNlRpNGXXUnJz\WS3Y3XzJJRp\SCjcH;weI9{cXNicnH0[UBqdmS3Y3XkJIJ6KFCOQVK=NFnjfYszOjd5OEe4NC=>
HT1080M3PHU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXO1NO69VQ>?MoPQO4Q>MUDpcohq[mm2czD0bIUh[2WubDDndo94fGhiaX7obYJqfGmxbjDjZZV{\WRiYomgZ49u[mmwZXSgeJJm[XSvZX70JI9nKESFQTDhcoQhV02SNFvjNI0zOjd2MEm4OC=>
A549 NFTZTW1CeG:ydH;zbZMhSXO|YYm=NGfFZVI2OM7:TR?=NH3CXo0zcA>?NHLOXGhx[XK2aXHscJkh\GWlcnXhd4V{KHOxZHn1cUB{\Wynbnn0[U1qdmS3Y3XkJIFxd3C2b4Ppdy=>NViydY1EOjJ5MkG4NFQ>
Primary OPCMV\BdI9xfG:|aYOgRZN{[Xl?MVex{txOM2juelZpNzJ2aB?=NILnOXlz\WS3Y3XzJJRp\SCyZYLj[Y51[WenIH;mJINmdGy|IHnuJIViemy7LTDhcoQhdGG2ZT3hdI9xfG:|aYOvcoVkem:|aYO=MW[yNlcxPzN6NR?=
PMNsM{H6cGFxd3C2b4Ppd{BCe3OjeR?=MmXoOFDPxE1?MVq2bC=>Ml[3SG1UVw>?MWTy[ZZmenOnZDD0bIUh[W2xdX70JI9nKGOuZXH2[YQh[2G|cHHz[U0{KHSxIH7lZZIhfmWqaXPs[UBt\X[nbIO=MlLUNlI3QTJ3N{e=
A549 M2i3Z2Fxd3C2b4Ppd{BCe3OjeR?=NIrYdIM2OM7:TR?=Mln6NYg>MoXmdJJmfmWwdIOgZZBweHSxc3nzJIlv\HWlZXSgZpkhSmGxaIXvd4ll\SCLMVyyNlY5PzZ|NR?=
AGSMmXJRZBweHSxc3nzJGF{e2G7NHS2S3kzOM7:TR?=NXrMempLOTKqM1zFPYlvcGmkaYTzJJRp\SCjY4TpeoF1cW:wIH;mJJBzdy2lYYPwZZNmNTNiaX6gdoV{eG:wc3WgeI8hfGinIFX0U2FkKG[{YXP0bY9vNVG2UZY4OjJ4OEezPVg>
shC9 NYS1fZRrSXCxcITvd4l{KEG|c3H5MlfDNVDPxE1?M37jVVE3cA>?MYficJVvfHNiU1jIJIV5eHKnc4Ppc44hcW5ic3jDPUBk\WyuczDlfJBwe2WmIITvJIVqfGincjDQRUBweiCOUFO=M{DDW|IzPjRzMEm0
primary MEFsNV;CW5VwTnWwY4Tpc44hSXO|YYm=MYWxNog>MXhCpIlv[3KnYYPld{BmfG:yb4Pp[IUucW6mdXPl[EBucXSxY3jvcoRzcWGuIH3lcYJz[W6nIHTldI9t[XKrenH0bY9vMUiyNlYyOzd4Nx?=
3T9 MEFsMmLySpVv[3Srb36gRZN{[Xl?Mn;wNVZpMoi5bY5kemWjc3XzJIN6fG:laILvcYUh[yC{ZXzlZZNmKGGodHXyJIV1d3Cxc3nk[U11emWjdH3lcpQ>NEDw[WQzOjZzM{e2Oy=>
3T9 MEFsMmLJSpVv[3Srb36gRZN{[Xl?MoXVNVhpNHrocph2eHKnZ4XsZZRmeyCrbnn0bYF1d3JiY3HzdIF{\S17IHL1eEBld3ewcnXneYxifGW|IHXm[oVkfG:{IHPhd5Bie2W|IHHmeIVzKGW2b4Dvd4ll\SC2cnXheI1mdnR?NWS5[5lXOjJ4MUO3Olc>
MDA-MB-231 NGTjbllCeG:ydH;zbZMhSXO|YYm=NWjYXnQ{OjEQvF2=MWC0[C=>NFzQc4Rz\WS3Y3XzJJRp\SClZXzsJIFxd3C2b4Ppd{BqdmS3Y3XkJIJ6KG2ndH\vdo1qdiC2cnXheI1mdnRid3HzJJNq\26rZnnjZY51dHl?NEjIOZEzOjV7M{S0NS=>
C6 NUXTbFZbSXCxcITvd4l{KEG|c3H5M4K4TFEx|ryPM1foSVI1cA>?NXfJZXlr[myxY3vzJJRp\SC|dYDwdoV{e2m4ZTDl[oZm[3Rib3[geIhmKHCncITp[IUhd25idnnhZoltcXS7MXmyNlU5QDl6MB?=
HL-60 MmPTRZBweHSxc3nzJGF{e2G7NFHoZVMyODEQvF2=MWCyOIg>NUnKUW5QcW6qaXLpeJMhfGinIHPlcIwh[XCxcITvd4l{KHOnbHXjeIVlKChtKT3t[Y51cHmuIN8yMUgy6obUNjmt[IlodHWlb4D5doFvd3OrZHZCpFU>M17pS|IzPTR4Nk[5
HL-60MWHBdI9xfG:|aYOgRZN{[Xl?M{\Xb|ExNThyzszNMX60bC=>NVPQSnA2cW6qaXLpeJMhXEeKUT3pcoR2[2WmIHPlcIwh[XCxcITvd4l{yqB?M2fMS|IzPTJ|MkK5
BCCMkW1RZBweHSxc3nzJGF{e2G7Mo\SOVDPxE1?M1PNSFFpMX\pcohq[mm2czDERXRUNW2nZHnheIVlKGe{b4f0bEBqdmirYnn0bY9vMXyyNlUyQTR|Nh?=
RAW 264.7NUTyTpJiSXCxcITvd4l{KEG|c3H5MmX2OVAwOTByzszNNGHmSmcycA>?M{L6PINwdmOnboTyZZRqd25vZHXw[Y5l\W62IHnubIljcXS|IFTPUk1qdmS3Y3XkJJJTVkFiY3zlZZZi\2V?M4fxO|IzPDlzNEK2
K562M3nqd2Fxd3C2b4Ppd{BCe3OjeR?=MUiyOe69VQ>?NH\BXnAzcA>?M{ezXJBz\X[nboTzJIFxd3C2b4Ppd{BqdmS3Y3XkJIJ6KGOxLYTy[YF1dWWwdDD3bZRpKGGvdYLlcpNqdiCJIHHu[EBVWkGLTB?=MlfCNlI1QDN5N{e=
SGC-7901Mk\vRZBweHSxc3nzJGF{e2G7NUnLdoJ1OjBizszNxsA>NGnjcoYzcA>?NUDtOmxp[XS2ZX71ZZRmeyCKMl:yxsBweiCWTl[g{tEucW6mdXPl[EBk\WyuIHHwc5B1d3OrczDhd{B4\WyuIHHzJINie3Cjc3WtN{Bi[3Srdnn0feKhMWOyNlQ4OTV6OR?=
PC3M1vU[GFxd3C2b4Ppd{BCe3OjeR?=NULIPFdrOTEQvF2=NVfEZoFSPGh?NH\1W3Vkd3WwdHXyd{BndGG4b3PvfIllNWmwZIXj[YQh[2G|cHHz[U1z\WyjdHXkJIFxd3C2b4Ppdy=>NW\ydoVNOjJ2N{G5O|Q>
SMMC-7721MmrGRZBweHSxc3nzJGF{e2G7MXm1NO69VQ>?NWnkS4xwPDiqMUjheJRmdnWjdHXzJI9VWi2rbnT1Z4VlKGGyb4D0c5Nqew>?NUL6cHJ[OjJ2NkW4N|M>
HeLa NYnhdVJESXCxcITvd4l{KEG|c3H5MmTkOVDDqM7:TR?=NGfkbFQ1NziqMYrpcohq[mm2czDTWHMucW6mdXPl[EBt[XSnLYDoZZNmKGGyb4D0c5Rq[yCndnXueJM>MYeyNlQ3ODVyNB?=
HeLa NEXKV3dCeG:ydH;zbZMhSXO|YYm=MmX6OVDDqM7:TR?=M2juSFFpM1u0NJN2eHC{ZYPz[ZMhfGinIF\SRXAucW6mdXPl[EBi[2O3bYXsZZRqd25ib3[gZY5v\XirbjDWJJBwe2m2aY\lJINmdGy|NYno[VBYOjJ2NEm0OFA>
T47D NHnt[29CeG:ydH;zbZMhSXO|YYm=M2XsXlExOM7:TR?=NYPrbYVJOWh?NGj4PJljdG:la4OgeIhmKGenbnXyZZRqd25ib3[gSU1k[WRxQ2TGNkBjgSCVVGO=NXW1b5lFOjJ2MEGxOlg>
HeLa MmL0RZBweHSxc3nzJGF{e2G7M3O3eVMx|ryPM3LF[VRpM2\rc:KhcW6lcnXhd4V{KHSqZTDn[Y5memGuIHPlcIwhfmmjYnnsbZR6KDR6IHigZYZ1\XJicHjveI9lgW6jbXnjJJRz\WG2bXXueOKhM1XYV|IzOzl2MkS4
HCCNWPGSnNxSXCxcITvd4l{KEG|c3H5MVuyNEDPxE4EoB?=MnrmNog>MlrOZZR1\W63YYTld{B1cGViRFjBJIlv\HWlZXSgZYN1cX[jdHnvckBw\iCSQWLQMX2yNlM1Ojd|Mh?=
mESCsMof2RZBweHSxc3nzJGF{e2G7MXiyMlXPxE1?NVHMbnZIOmh?M2fBZYlvcGmkaYTzJJRp\SCQYV[tcYVlcWG2ZXSgZ4F{eGG|ZTDhZ5RqfmG2aX;uNUPxS|JyOjJ{OEWyO|Q>
EMT-6 Mn31R5l1d3SxeHnjbZR6KEG|c3H5NV\DdFBXOTByzszNNHPjNG0ycA>?M1njd5BienSrYXzsfUBjdG:la3XkJINmdGxiZHXheIghcW6mdXPl[EBjgSC|aYLhcYV{cW6nM4LEbFIzOjVzOUKx
MCF7MY\BdI9xfG:|aYOgRZN{[Xl?MmDzOVDDqM7:TR?=NX3XZ2pPOWh?M4jocIlvcGmkaYTzJHBCKGGldHn2ZZRm\CClYYPwZZNmNTNuID25MEBidmRicH;sfUhCTFBvcnnic5NmMSCyb3z5cYVz[XOnMXiyNlIzOzN2NR?=
K562NIG0XJlCeG:ydH;zbZMhSXO|YYm=NYHMcJFqOjBizszNxsA>NGO4eoU1QGh?NGHsTnNFVVORM4\wSIJtd2OtczDsZZBifGmwaXKtbY5lfWOnZDDpcohq[mm2aX;uJI9nKH[rYXLpcIl1gSCjbnSgZZBweHSxc3nzJIlv\HWldHnvci=>NVrzUVR[OjJ{MU[xOVg>
Molt4-hygM1nscGFxd3C2b4Ppd{BCe3OjeR?=NV[xcZJnOTEQvF2=M3rvWlAvPWh?M17WO4Jtd2OtczDmZZJv\XOxbD3pcoR2[2WmIHPhd5Bie2VvMz3sbYtmKGGldHn2bZR6NGLLTlczPjJ5NUixNS=>
HeLaMYPBdI9xfG:|aYOgRZN{[Xl?NIDaZocyOM7:TR?=NI\COG4xNjWqMoHnbY5pcWKrdIOgZZBweHSxc3nzJIlv\HWlZXSgZpkhfGinIHPvcYJqdmWmIITy[YF1dWWwdDD3bZRpKGexbXnzbY4hViCjbnSgWHJCUUx?M4Dn[|IzOTd7Nk[x
Jurkat TNH\j[XhCeG:ydH;zbZMhSXO|YYm=M2LSXlMx|ryPMnnFNE42cA>?NXHzW5gzTE2VTx?=MoflZoxw[2u|IITo[UB7cXKjbT3pcoR2[2WmIHHwc5B1d3Orcx?=MVmyNlE2QTh7OB?=
NeutrophilNHzYRpdCeG:ydH;zbZMhSXO|YYm=NYPiXJVNOjEQvF2=NUT2Sot1OC53aB?=MVzheJRmdnWjdHXzJJRp\SCycn:tZZBweHSxdHnjJIVn\mWldDDv[kBO[VJzM3TkfVI3OTl4OES0
HCT116M3vCdGFxd3C2b4Ppd{BCe3OjeR?=NUT6NW5vPTEEoN88US=>M{CxbFJpMnPNdoV3\XK|ZYOgd5lv\XKpaYP0bYMh[XCxcITvd4l{KGWoZnXjeJMhd2ZiY3Xs[YNwgGmkIHHu[EBPWENvMUdCpC=>NHXFb|gzOjF3OUe1Ni=>
MDA-MB-231 NWrjcWJNSXCxcITvd4l{KEG|c3H5M4fHXlIvPS15LkZOwG0>NVLBd5cxOmh?NEjqNXpqdmirYnn0d{B1cGViY3XscEBl\WG2aDDv[kBOTEFvTVKtNlMyKGOnbHzzJIlv\HWlZXSgZpkhW0SWIHnuJIEh[2:wY3XueJJifGmxbjDk[ZBmdmSnboSgcYFvdmW{MlvSNlIyOTV3Mk[=
LNCaPMWHBdI9xfG:|aYOgRZN{[Xl?NUXFXGlIPDEQvF2=NIXNVYczcA>?NI\TTGFqdmirYnn0d{BjfXSnaX6gbY5lfWOnZDDj[YxtKGGyb4D0c5Nqew>?MV6yNlEyPDd4NB?=
MB231NFjzb4dCeG:ydH;zbZMhSXO|YYm=MUSxNFDPxE1?MXexbC=>NF\CfJpFVVORM3PqUoFjem:pYYTld{B1cGViaX7keYN1cW:wIH;mJINmdGxiZHXheIgh[nliV1XFNUBqdmirYnn0bY9vNCCWUlHJUEB1emWjdH3lcpQtKGGwZDD0bIUh[2:vYnnuZZRqd25?NX7UeWRbOjJzMUK5OFA>
HCC38 MV\BdI9xfG:|aYOgRZN{[Xl?MVKxNFDPxE1?MnXHNYg>MWLEUXNQNH3MO5Bi[nKxZ3H0[ZMhfGinIHnu[JVkfGmxbjDv[kBk\WyuIHTlZZRpKGK7IGfFSVEhcW6qaXLpeIlwdixiVGLBTWwhfHKnYYTt[Y51NCCjbnSgeIhmKGOxbXLpcoF1cW:wMU[yNlEyOjl2MB?=
MDA-MB231M3;WO2Fxd3C2b4Ppd{BCe3OjeR?=NXy4dpNTPTEEoN88US=>MX2yOIg>M1O2SWROW09?NF;NOFhi[nKxZ3H0[ZMh[3W{Y4XtbY4ucW6mdXPl[EBk\WyuIHTlZZRpMX2yNlExOTN|NR?=
LNCaPM2q0VmFxd3C2b4Ppd{BCe3OjeR?=NUnOS5ZzPTEEoN88US=>NXX4OYNyOjSqMof2SG1UVw>?NUDKWlh6[WK{b3fheIV{KGO3cnP1cYlvNWmwZIXj[YQh[2WubDDk[YF1cA>?MorKNlIyODF|M{W=
HCT116MVfBdI9xfG:|aYOgRZN{[Xl?Ml\wOVDDqM7:TR?=NG\jU2kzPGh?M4TD[2ROW09?MVvhZpJw\2G2ZYOgZ5Vz[3WvaX6tbY5lfWOnZDDj[YxtKGSnYYToMl\ONlIyODF|M{W=
Ishikawa NHPFd3RCeG:ydH;zbZMhSXO|YYm=MVSyOe69VQ>?NHjqb5QzPGh?MXvy[YR2[2W|IHPlcIwh\GWjdHigZY5lKGGyb4D0c5NqeyCrbnT1Z4VlKGK7IFLh[kBCOQ>?NFHFTnIzOjB6OEmxPC=>
 YD-8 NXGyV4p5SXCxcITvd4l{KEG|c3H5MX6xNFDPxE1?M3;yc|FpM3vK[IlvcGmkaYTzJHBNTU9vaX7keYNm\CCjcH;weI9{cXN?NISy[VkzOjB6NkG4Ny=>
eosinophil NV;Cco0{SXCxcITvd4l{KEG|c3H5MmrWPVDPxE1?NUP1WlBoOjSqMVfpcohq[mm2czDhdI9xfG:|aYOgbY5lfWOnZDDifUBH[XNiYX70bYJw\HoEoB?=NXjOT3l1OjJyN{mzN|Q>
L929M4nUT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX7zcXYxOi53zszNM{f3WVI1cA>?MWLpcohq[mm2czD0bIUh\XiycnXzd4lwdiCxZjDwMZA{QCCjbnSgUmYu|rqEIITvJIF2\22nboSgWG5H|rFvaX7keYNm\CCwZXPyc5B1d3OrczDhcoQh[XW2b4DoZYd6NYTTfZBXOjJyMkewPVc>
YD-8 MlX6RZBweHSxc3nzJGF{e2G7NFXzZYMyODEQvF2=NFW1b5IycA>?MnmzZoxw[2u|IITo[UBIWy2KQ3ytbY5lfWOnZDDhdI9xfG:|aYO=M13yXVIzODJyMEe4
HBxMkj1RZBweHSxc3nzJGF{e2G7MWSyOe69VQ>?NEXndXo1QGh?NYfiPHZyTE2VTx?=M{ewdZJm\HWlZXSgZ4VtdCCmZXH0bEBqdmS3Y3XkJIJ6KDNvTVG=NXX3V5RWOjJyMkCwO|g>
U937 M4fS[WFxd3C2b4Ppd{BCe3OjeR?=MnjTOVDDqM7:TR?=M{LlblFpNITxNoRqdmirYnn0d{BJTi2rbnT1Z4VlKGGyb4D0c5Nqe8LiM3nVOVIyQTl6N{Ox
HL60NYrRVGs2SXCxcITvd4l{KEG|c3H5MVS0NO69VQ>?MXm0NI1qdg>?NHroOI9FVVORMn\qZoxw[2u|IFLOSGMh[2:vcH;1coR{KGmwZIXj[UBmgHCxc4Xy[UBw\iCyaH;zdIhifGmmeXzz[ZJqdmViYX7kJGRPSSCocnHncYVvfGG2aX;uMVSyNVk5OzJ7Nh?=
M-14MYXBdI9xfG:|aYOgRZN{[Xl?MkTjNlXPxE1?MkLiNE42cA>?NFHVUWzDqGmwaHnibZR{KGKxdHigeIhmKGO{dXTlJIV5fHKjY4StJIFv\CClb33wc5Vv\C2rbnT1Z4VlKGGyb4D0c5Nqew>?MVuyNVk2PDl3OR?=
SK-BR-3M2DqV2Fxd3C2b4Ppd{BCe3OjeR?=M3PpV|UxyqEQvF2=MYOybC=>M3nZVIJtd2OtczDhdI9xfG:2aXOgSG5CKG[{YXft[Y51[XSrb36gbY5lfWOnZDDifUBkd22kaX7heIlwdiCxZjDTUU0yPjRiYX7kJJJi\GmjdHnvci=>MYKyNVkxOTN6Nh?=
MDA-MB-468NEDxVo5CeG:ydH;zbZMhSXO|YYm=NWfMZ5NLPTEEoN88US=>MVOybC=>NYDWRWJm[myxY3vzJIFxd3C2b4TpZ{BFVkFiZoLh[41mdnSjdHnvckBqdmS3Y3XkJIJ6KGOxbXLpcoF1cW:wIH;mJHNONTF4NDDhcoQhemGmaXH0bY9vM2O4dlIyQTBzM{i2

... Click to View More Cell Line Experimental Data

In vivo
Features A key compound for apoptosis studies.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Slee EA, et al. Biochem J, 1996, 315 (Pt 1), 21-24.

[2] Shimizu T, et al. Leukemia, 1997, 11(8), 1238-1244.

view more

Chemical Information

Download Z-VAD-FMK SDF
Molecular Weight (MW) 467.49
Formula

C22H30FN3O7

CAS No. 187389-52-2
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 93 mg/mL (198 mM)
Water <1 mg/mL (<1 mM)
Ethanol 24 mg/mL warmed (51 mM)
DMF 84 mg/mL
* Z-VAD-FMK will racemize in DMSO, water and ethanol.
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name L-Alaninamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-3-fluoro-1-(2-methoxy-2-oxoethyl)-2-oxopropyl]-

Customer Product Validation (2)


Click to enlarge
Rating
Source Acta Pharmacol Sin 2014 35(4):531-9. Z-VAD-FMK purchased from Selleck
Method Western blot
Cell Lines SaOS2 human osteosarcoma cells
Concentrations 10 uM
Incubation Time 24 h
Results To investigate the effect of the caspase inhibitor zVAD-fmk on the icaritin-induced apoptosis, it performed Western blot analysis to evaluate the levels of cleaved caspase-3. It found that the caspase inhibitor zVAD-fmk could decrease the icaritin-induced caspase-3 expression in the zVAD-fmk+icaritin-treated group compared to the icaritin-treated group (P<0.05).

Click to enlarge
Rating
Source Med Oncol, 2015, 32(4): 538 . Z-VAD-FMK purchased from Selleck
Method Western Blot
Cell Lines Gastrocnemius muscles
Concentrations 1.5 mg/kg
Incubation Time 5、12 days
Results Results from western blot analyses showed that ATF2 levels were higher in the tumor-bearing animals than in the healthy controls. ATF2 levels in the groups treated with CFZ, z-VAD-fmk, or CFZ + z-VAD-fmk, at either 5 or 12 days after inoculation, were lower than in the CC group (treated with PBS).

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related Caspase Products

  • MI-773 (SAR405838)

    MI-773 (SAR405838) is an orally available MDM2 antagonist with Ki of 0.88 nM. Phase 1.

  • A-1210477

    A-1210477 is a potent and selective MCL-1 inhibitor with Ki and IC50 of 0.454 nM and 26.2 nM, respectively, >100-fold selectivity over other Bcl-2 family members.

  • Belnacasan (VX-765)

    Belnacasan (VX-765) is a potent and selective inhibitor of caspase-1 with Ki of 0.8 nM in a cell-free assay. Phase 2.

    Features:A potent and selective inhibitor of interleukin-converting enzyme/caspase-1.

  • PAC-1

    PAC-1 is a potent procaspase-3 activator with EC50 of 0.22 μM and the first small molecule known to directly activate procaspase-3 to caspase-3.

    Features:The first small molecule known to directly activate procaspase-3 to caspase-3.

  • Apoptosis Activator 2

    Apoptosis Activator 2 strongly induces caspase-3 activation, PARP cleavage, and DNA fragmentation which leads to the destruction of cells (Apaf-1 dependent) with IC50 of ~4 μM, inactive to HMEC, PREC, or MCF-10A cells.

  • Tasisulam

    Tasisulam is an antitumor agent and an apoptosis inducer via the intrinsic pathway. Phase 3.

  • ABT-263 (Navitoclax)

    ABT-263 (Navitoclax) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with Ki of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.

  • Venetoclax (ABT-199, GDC-0199)

    Venetoclax (ABT-199, GDC-0199) is a Bcl-2-selective inhibitor with Ki of <0.01 nM in cell-free assays, >4800-fold more selective versus Bcl-xL and Bcl-w, and no activity to Mcl-1. Phase 3.

    Features:Re-engineered version of ABT-263 (Navitoclax).

Recently Viewed Items

Tags: buy Z-VAD-FMK | Z-VAD-FMK supplier | purchase Z-VAD-FMK | Z-VAD-FMK cost | Z-VAD-FMK manufacturer | order Z-VAD-FMK | Z-VAD-FMK distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us